Father and Son 982x327px

Fuel Our Fight

ACKC is the only major
kidney cancer grassroots
advocacy organization
raising money that goes
predominantly to fund
kidney cancer research

Donate Today
Capitol 982x327px

Annual Campaign
for Federal
Research Funding

ACKC's Capitol Hill initiative
to get a $15M appropriation
for kidney cancer research

Sign Up for 2017
Researcher A 982x327px

Direct Funding
to Kidney Cancer
Researchers

Since 2006, ACKC has
granted more than $350,000
to promising researchers

Learn More
Man with MD 982 x 327px

Advocacy for
Special Funding
Initiatives

ACKC’s work on Capitol Hill
resulted in increased support
for federal research projects.

Learn More
Holding Hand 982x327px

Patient Guides:
Taking Charge of
Kidney Cancer

Updated in 2016, ACKC’s
online pamphlets empower
patients and their caregivers

View the Guides
Slide background

Stay Connected

Join ACKC’s online
community of survivors,
caregivers, family and
friends by liking us
on Facebook…we’re
13,049 members strong!

Join Us Online

ACKC Point of View

  • The Cost of Cancer Medication

    Why are cancer drug prices skyrocketing? What can be done to rein in costs when drug companies are a “corporate monopoly” with the highest profits of any industry? The patient power of grass-roots groups such as ACKC may hold the solution, says Hagop Kantarjian, M.D., a leader in the in the fight to lower drug costs. Full article coming soon…

News

  • House Appropriations Committee Approves $10M for Kidney Cancer Research

    May 19, 2016

    After years of advocacy emphasizing the lack of kidney cancer federal funding, on Tuesday, May 17th, the House Appropriations Committee approved the FY17 Defense Appropriations Act and forwarded the bill to the full House.  The fiscal year 2017 Defense appropriations bill includes a $10 million line item within the Defense Health Program, Congressional Directed Medical Research Program for kidney cancer research. This is great news for the kidney cancer community. If this legislation is enacted,… More →



  • 13 Must-Read Books for Oncologists

    January 7, 2016

    The following books were recommended for reading to oncologists by the editors of the oncology journal, Cancer Network. Happy reading!  



  • ACKC Action Pays Off in Congress Budget Deal

    December 19, 2015

    Congress highlights need for National Cancer Institute to increase attention to kidney cancer research and its early detection efforts. Yesterday (December 18, 2015), Congress passed the $1.8 trillion omnibus appropriation bill for Fiscal Year 2016 (October 1, 2015 – September 30, 2016). The bill calls for an increase of $2 billion in the NIH budged and $264 million in the National Cancer Institute’s budget, bringing the latter to $5.2 billion. This is good news considering… More →



  • DoD Award for Enhancing Immune Checkpoint Inhibitors

    October 19, 2015

      Hans Hammers from Johns Hopkins Cancer Center won an Idea Award from the Department of Defense for Fiscal Year 2014 for “Enhancing Immune Checkpoint Inhibitor[1] Therapy in Kidney Cancer”. This is a two-year grant in the amount of $486,000 awarded to Dr. Hammers and Johns Hopkins. DoD grants have normally gone to pure researchers, but Dr. Hammers, aside from doing research, is also an eminent clinical oncologist who has made a number of presentations… More →



  • Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab

    July 14, 2015

    Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Jul. 13, 2015 — Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of a phase 1 trial of cabozantinib in combination with nivolumab alone or in combination with nivolumab plus ipilimumab in patients with advanced/metastatic urothelial (bladder) and other genitourinary tumors…. More →